
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8593888/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A pregnancy to remember: trained immunity of the uterine mucosae. Mucosal Immunology, 2021, 14, 539-541.	6.0	5
2	Complement factor D haplodeficiency is associated with a reduced complement activation speed and diminished bacterial killing. Clinical and Translational Immunology, 2021, 10, e1256.	3.8	2
3	Thyrotrophin and thyroxine support immune homeostasis in humans. Immunology, 2021, 163, 155-168.	4.4	12
4	Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients. Journal of Allergy and Clinical Immunology, 2021, 148, 1030-1040.	2.9	25
5	Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma. Clinical Chemistry, 2021, 67, 867-875.	3.2	12
6	Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane. International Immunopharmacology, 2021, 93, 107404.	3.8	2
7	Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients. Blood Advances, 2020, 4, 3615-3620.	5.2	27
8	Successful Regulatory T Cell-Based Therapy Relies on Inhibition of T Cell Effector Function and Enrichment of FOXP3+ Cells in a Humanized Mouse Model of Skin Inflammation. Journal of Immunology Research, 2020, 2020, 1-11.	2.2	0
9	Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels. Autoimmunity Reviews, 2020, 19, 102515.	5.8	17
10	Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins. Clinical Chemistry, 2020, 66, 421-433.	3.2	41
11	Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients. American Journal of Transplantation, 2019, 19, 2926-2933.	4.7	32
12	Antibodies against ARHGDIB are associated with long-term kidney graft loss. American Journal of Transplantation, 2019, 19, 3335-3344.	4.7	46
13	<p>Increased dermal expression of chromatin-associated protein HMGB1 and concomitant T-cell expression of the DNA RAGE in patients with psoriasis vulgaris</p> . Psoriasis: Targets and Therapy, 2019, Volume 9, 7-17.	2.2	12
14	Long-Term Effects of Experimental Human Endotoxemia on Immune Cell Function: Similarities and Differences With Sepsis. Shock, 2019, 51, 678-689.	2.1	10
15	Metabolic Pathways Involved in Regulatory T Cell Functionality. Frontiers in Immunology, 2019, 10, 2839.	4.8	104
16	Toward a Sensible Single-antigen Bead Cutoff Based on Kidney Graft Survival. Transplantation, 2019, 103, 789-797.	1.0	31
17	Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients. Nephrology Dialysis Transplantation, 2019, 34, 1417-1422.	0.7	7
18	Selective expansion and CMV-dependency in pregnancy trained human endometrial NK cells. Cellular and Molecular Immunology, 2019, 16, 410-411.	10.5	15

#	Article	IF	CITATIONS
19	A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival. Nephrology Dialysis Transplantation, 2019, 34, 1056-1063.	0.7	17
20	Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant. American Journal of Transplantation, 2018, 18, 2274-2284.	4.7	65
21	How uterine microbiota might be responsible for a receptive, fertile endometrium. Human Reproduction Update, 2018, 24, 393-415.	10.8	176
22	Endometrial natural killer (NK) cells reveal a tissue-specific receptor repertoire. Human Reproduction, 2018, 33, 441-451.	0.9	34
23	TNF-α–induced protein 3 (TNFAIP3) /A20 acts as a master switch in TNF-α blockade–driven IL-17A expression Journal of Allergy and Clinical Immunology, 2018, 142, 517-529.	<sup>.</sup> 2.9	52
24	Development and Validation of a Multiplex Non-HLA Antibody Assay for the Screening of Kidney Transplant Recipients. Frontiers in Immunology, 2018, 9, 3002.	4.8	25
25	Integration of multi-omics data and deep phenotyping enables prediction of cytokine responses. Nature Immunology, 2018, 19, 776-786.	14.5	103
26	MPZL2, Encoding the Epithelial Junctional Protein Myelin Protein Zero-like 2, Is Essential for Hearing in Man and Mouse. American Journal of Human Genetics, 2018, 103, 74-88.	6.2	34
27	Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure. Journal of the American Society of Nephrology: JASN, 2018, 29, 2279-2285.	6.1	25
28	PIRCHE-II Is Related to Graft Failure after Kidney Transplantation. Frontiers in Immunology, 2018, 9, 321.	4.8	63
29	An Autocrine TNFα–Tumor Necrosis Factor Receptor 2 Loop Promotes Epigenetic Effects Inducing Human Treg Stability In Vitro. Frontiers in Immunology, 2018, 9, 573.	4.8	39
30	Stabilizing human regulatory T cells for tolerance inducing immunotherapy. Immunotherapy, 2017, 9, 735-751.	2.0	10
31	OR41 PIRCHE-II: A novel tool to identify permissible HLA mismatches in kidney transplantation. Human Immunology, 2017, 78, 39.	2.4	1
32	Polymorphisms in <i>CD84</i> , <i>IL12B</i> and <i>TNFAIP3</i> are associated with response to biologics in patients with psoriasis. British Journal of Dermatology, 2017, 176, 1288-1296.	1.5	42
33	Embracing Complexity beyond Systems Medicine: A New Approach to Chronic Immune Disorders. Frontiers in Immunology, 2016, 7, 587.	4.8	24
34	A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells. PLoS ONE, 2016, 11, e0156311.	2.5	59
35	High mobility group box 1 is increased in the sera of psoriatic patients with disease progression. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 435-441.	2.4	26
36	Inflammation-associated changes in lipid composition and the organization of the erythrocyte membrane. BBA Clinical, 2016, 5, 186-192.	4.1	49

#	Article	IF	CITATIONS
37	Understanding human immune function using the resources from the Human Functional Genomics Project. Nature Medicine, 2016, 22, 831-833.	30.7	63
38	How can we reduce costs of solidâ€phase multiplexâ€bead assays used to determine antiâ€< scp>HLA antibodies?. Hla, 2016, 88, 110-119.	0.6	15
39	Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin. Blood, 2016, 127, 1976-1986.	1.4	102
40	Added effects of dexamethasone and mesenchymal stem cells on early Natural Killer cell activation. Transplant Immunology, 2016, 37, 1-9.	1.2	26
41	Cell Surface Expression of HLA-Cw6 by Human Epidermal Keratinocytes: Positive Regulation by Cytokines, Lack of Correlation to a Variant Upstream of HLA-C. Journal of Investigative Dermatology, 2016, 136, 1903-1906.	0.7	5
42	Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. PeerJ, 2016, 4, e2300.	2.0	55
43	KIR and Human Leukocyte Antigen Genotype Associated Risk of Cytomegalovirus Disease in Renal Transplant Patients. Transplantation, 2015, 99, 1506-1513.	1.0	10
44	Cytokine Release After Treatment With Rituximab in Renal Transplant Recipients. Transplantation, 2015, 99, 1907-1911.	1.0	11
45	Prominent HLA-G Expression in Liver Disease But Not After Liver Transplantation. Transplantation, 2015, 99, 2514-2522.	1.0	6
46	Lowâ€affinity <scp>TCR</scp> engagement drives <scp>IL</scp> â€2â€dependent postâ€ŧhymic maintenance of naive <scp>CD</scp> 4+ T cells in aged humans. Aging Cell, 2015, 14, 744-753.	6.7	43
47	Soluble CD30 does not predict late acute rejection or safe tapering of immunosuppression in renal transplantation. Transplant Immunology, 2015, 32, 18-22.	1.2	18
48	Rituximab as Induction Therapy After Renal Transplantation: A Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety. American Journal of Transplantation, 2015, 15, 407-416.	4.7	96
49	Quantitative Measurement of Immunoglobulins and Free Light Chains Using Mass Spectrometry. Analytical Chemistry, 2015, 87, 8268-8274.	6.5	27
50	Balance of Treg versus Tâ€effector cells during systemic treatment with adalimumab and topical treatment with calcipotriol–betamethasone dipropionate ointment. Experimental Dermatology, 2015, 24, 65-67.	2.9	13
51	Targeting PKC in Human T Cells Using Sotrastaurin (AEB071) Preserves Regulatory T Cells and Prevents IL-17 Production. Journal of Investigative Dermatology, 2014, 134, 975-983.	0.7	37
52	Anti-B cell therapy with rituximab as induction therapy in renal transplantation. Transplant Immunology, 2014, 31, 207-209.	1.2	6
53	The PROCARE consortium: Toward an improved allocation strategy for kidney allografts. Transplant Immunology, 2014, 31, 184-190.	1.2	25
54	The interplay between antiviral immunity and allo-immune reactivity after renal transplantation. Transplant Immunology, 2014, 31, 191-194.	1.2	2

#	Article	IF	CITATIONS
55	Redefining Strategies to Introduce Tolerance-Inducing Cellular Therapy in Human beings to Combat Autoimmunity and Transplantation Reactions. Frontiers in Immunology, 2014, 5, 392.	4.8	2
56	Selective expansion of human natural killer cells leads to enhanced alloreactivity. Cellular and Molecular Immunology, 2014, 11, 160-168.	10.5	14
57	In Vivo Induction of Cutaneous Inflammation Results in the Accumulation of Extracellular Trap-Forming Neutrophils Expressing RORÎ <sup>3</sup> t and IL-17. Journal of Investigative Dermatology, 2014, 134, 1276-1284.	0.7	107
58	Cellular sources of <scp>IL</scp> â€17 in psoriasis: a paradigm shift?. Experimental Dermatology, 2014, 23, 799-803.	2.9	109
59	Crosstalk between Keratinocytes and T Cells in a 3D Microenvironment: A Model to Study Inflammatory Skin Diseases. Journal of Investigative Dermatology, 2014, 134, 719-727.	0.7	120
60	Menstrual blood closely resembles the uterine immune micro-environment and is clearly distinct from peripheral blood. Human Reproduction, 2014, 29, 303-314.	0.9	62
61	Longitudinal Analysis of T and B Cell Phenotype and Function in Renal Transplant Recipients with or without Rituximab Induction Therapy. PLoS ONE, 2014, 9, e112658.	2.5	39
62	Phosphatidylserine exposure on stored red blood cells as a parameter for donor-dependent variation in product quality. Blood Transfusion, 2014, 12, 204-9.	0.4	49
63	CD19 Is a Useful B Cell Marker After Treatment With Rituximab: Comment on the Article by Jones et al. Arthritis and Rheumatism, 2013, 65, 1130-1131.	6.7	9
64	The effects of in vivo B-cell depleting therapy on ex-vivo cytokine production. Transplant Immunology, 2013, 28, 183-188.	1.2	4
65	Heritable and non-heritable genetic effects on retained placenta in Meuse-Rhine-Yssel cattle. Animal Reproduction Science, 2013, 137, 1-7.	1.5	12
66	High-Dose Vitamin D <sub>3</sub> Supplementation Is a Requisite for Modulation of Skin-Homing Markers on Regulatory T Cells in HIV-Infected Patients. AIDS Research and Human Retroviruses, 2013, 29, 299-306.	1.1	10
67	Co-culture of healthy human keratinocytes and T-cells promotes keratinocyte chemokine production and RORγt-positive IL-17 producing T-cell populations. Journal of Dermatological Science, 2013, 69, 44-53.	1.9	21
68	A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function. American Journal of Transplantation, 2013, 13, 1503-1511.	4.7	126
69	Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin. British Journal of Dermatology, 2013, 168, 1294-1302.	1.5	40
70	Iron Status and Systemic Inflammation, but Not Gut Inflammation, Strongly Predict Gender-Specific Concentrations of Serum Hepcidin in Infants in Rural Kenya. PLoS ONE, 2013, 8, e57513.	2.5	47
71	Koebner Phenomenon in Psoriasis Is Not Associated with Deletion of Late Cornified Envelope Genes LCE3B and LCE3C. Journal of Investigative Dermatology, 2012, 132, 475-476.	0.7	7
72	Functional consequences of sphingomyelinase-induced changes in erythrocyte membrane structure. Cell Death and Disease, 2012, 3, e410-e410.	6.3	76

#	Article	IF	CITATIONS
73	Rho Kinase Inhibitor Y-27632 Prolongs the Life Span of Adult Human Keratinocytes, Enhances Skin Equivalent Development, and Facilitates Lentiviral Transduction. Tissue Engineering - Part A, 2012, 18, 1827-1836.	3.1	32
74	Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunology, Immunotherapy, 2012, 61, 2003-2011.	4.2	24
75	Paediatric-onset psoriasis is associated with <i>ERAP1</i> and <i>IL23R</i> loci, <i>LCE3C_LCE3B</i> deletion and <i>HLA-C*06</i> . British Journal of Dermatology, 2012, 167, 922-925.	1.5	31
76	Translating the role of vitamin D <sub>3</sub> in infectious diseases. Critical Reviews in Microbiology, 2012, 38, 122-135.	6.1	74
77	Defining Early Human NK Cell Developmental Stages in Primary and Secondary Lymphoid Tissues. PLoS ONE, 2012, 7, e30930.	2.5	69
78	In Vitro Effects of Rituximab on the Proliferation, Activation and Differentiation of Human B Cells. American Journal of Transplantation, 2012, 12, 341-350.	4.7	35
79	Seasonal Variation in Vitamin D3 Levels Is Paralleled by Changes in the Peripheral Blood Human T Cell Compartment. PLoS ONE, 2012, 7, e29250.	2.5	62
80	Anaphylaxis from Passive Transfer of Peanut Allergen in a Blood Product. New England Journal of Medicine, 2011, 364, 1981-1982.	27.0	67
81	Analyzing the Homeostasis of Signaling Proteins by a Combination of Western Blot and Fluorescence Correlation Spectroscopy. Biophysical Journal, 2011, 101, 2807-2815.	0.5	7
82	Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A-Producing Cells and Are Found in Lesional Skin. Journal of Investigative Dermatology, 2011, 131, 1853-1860.	0.7	350
83	Vitamin D3 down-regulates proinflammatory cytokine response to Mycobacterium tuberculosis through pattern recognition receptors while inducing protective cathelicidin production. Cytokine, 2011, 55, 294-300.	3.2	90
84	Donor and recipient HLA/KIR genotypes do not predict liver transplantation outcome. Transplant International, 2011, 24, 932-942.	1.6	13
85	Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clinical and Experimental Immunology, 2011, 164, 72-79.	2.6	153
86	1,25-Dihydroxyvitamin D3 inhibits proliferation but not the suppressive function of regulatory T cells in the absence of antigen-presenting cells. Immunology, 2011, 134, 459-468.	4.4	58
87	Mycophenolic Acid-Mediated Suppression of Human CD4+ T Cells: More Than Mere Guanine Nucleotide Deprivation. American Journal of Transplantation, 2011, 11, 439-449.	4.7	70
88	1,25-dihydroxyvitamin D3 Modulates Cytokine Production Induced by Candida albicans: Impact of Seasonal Variation of Immune Responses. Journal of Infectious Diseases, 2011, 203, 122-130.	4.0	66
89	DNA-PKcs Controls an Endosomal Signaling Pathway for a Proinflammatory Response by Natural Killer Cells. Science Signaling, 2010, 3, ra14.	3.6	54
90	Natural Killer Cells and HLA-G Expression in the Basal Decidua of Human Placenta Adhesiva. Placenta, 2010, 31, 1078-1084.	1.5	7

#	Article	IF	CITATIONS
91	Rapamycin and MPA, But Not CsA, Impair Human NK Cell Cytotoxicity Due to Differential Effects on NK Cell Phenotype. American Journal of Transplantation, 2010, 10, 1981-1990.	4.7	75
92	CD3+/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia, 2010, 24, 583-591.	7.2	26
93	What is Your Guess? Detecting Only Light Chains, Now What?. Clinical Chemistry, 2010, 56, 1368-1368.	3.2	1
94	High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy. PLoS ONE, 2010, 5, e9221.	2.5	150
95	The number of multinucleated trophoblastic giant cells in the basal decidua is decreased in retained placenta. Journal of Clinical Pathology, 2009, 62, 794-797.	2.0	8
96	Immunotherapy with regulatory T cells in transplantation. Immunotherapy, 2009, 1, 855-871.	2.0	11
97	The Inhibitory FcγIIb Receptor Dampens TLR4-Mediated Immune Responses and Is Selectively Up-regulated on Dendritic Cells from Rheumatoid Arthritis Patients with Quiescent Disease. Journal of Immunology, 2009, 183, 4509-4520.	0.8	52
98	Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients. Clinical Cancer Research, 2009, 15, 2531-2540.	7.0	172
99	Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nature Genetics, 2009, 41, 211-215.	21.4	482
100	Complete genomic sequence of a novel HLAâ€B allele, B*4456N. Tissue Antigens, 2009, 73, 607-609.	1.0	4
101	The Macrophage Mannose Receptor Induces IL-17 in Response to Candida albicans. Cell Host and Microbe, 2009, 5, 329-340.	11.0	294
102	KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients. Molecular Immunology, 2008, 45, 3631-3638.	2.2	33
103	A novel (Leu183Pro-)mutation in the HFE-gene co-inherited with the Cys282Tyr mutation in two unrelated Dutch hemochromatosis patients. Blood Cells, Molecules, and Diseases, 2008, 40, 334-338.	1.4	10
104	Ex Vivo Generation of Human Alloantigen-Specific Regulatory T Cells from CD4posCD25high T Cells for Immunotherapy. PLoS ONE, 2008, 3, e2233.	2.5	82
105	Immunological Monitoring of Renal Transplant Recipients to Predict Acute Allograft Rejection Following the Discontinuation of Tacrolimus. PLoS ONE, 2008, 3, e2711.	2.5	44
106	Clinical Grade Treg: GMP Isolation, Improvement of Purity by CD127pos Depletion, Treg Expansion, and Treg Cryopreservation. PLoS ONE, 2008, 3, e3161.	2.5	105
107	Soluble HLA-G promotes Th1-type cytokine production by cytokine-activated uterine and peripheral natural killer cells. Molecular Human Reproduction, 2007, 13, 123-133.	2.8	84
108	The immunosuppressive drug FK778 induces regulatory activity in stimulated human CD4+CD25â^' T cells. Blood, 2007, 109, 244-252.	1.4	21

#	Article	IF	CITATIONS
109	The Presence of Donor-Specific Human Leukocyte Antigen Antibodies Does Not Preclude Successful Withdrawal of Tacrolimus in Stable Renal Transplant Recipients. Transplantation, 2007, 84, 1092-1096.	1.0	5
110	KIR Gene and KIR Ligand Analysis to Predict Graft Rejection After Renal Transplantation. Transplantation, 2007, 84, 1045-1051.	1.0	23
111	Allogeneic stimulation of naturally occurring CD4+CD25+ T cells induces strong regulatory capacity with increased donor-reactivity. Transplant Immunology, 2007, 17, 237-242.	1.2	10
112	Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+CD25+FoxP3+ T cells. Bone Marrow Transplantation, 2007, 39, 537-545.	2.4	138
113	Following Anti-CD25 Treatment, A Functional CD4+CD25+ Regulatory T-Cell Pool Is Present in Renal Transplant Recipients. American Journal of Transplantation, 2007, 7, 249-255.	4.7	79
114	Antigen-Specific Regulatory T-Cell Subsets in Transplantation Tolerance. Human Immunology, 2006, 67, 665-675.	2.4	14
115	Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood, 2006, 107, 1018-1023.	1.4	230
116	Exon 2 sequence analysis of a novel HLA-DRB1 allele, DRB1*1520. Tissue Antigens, 2006, 68, 347-348.	1.0	5
117	Exon 2 sequence analysis of a novel HLA-DRB1 allele, DRB1*1460. Tissue Antigens, 2006, 68, 346-347.	1.0	4
118	Ex vivo expansion of human CD4+CD25high regulatory T cells from transplant recipients permits functional analysis of small blood samples. Journal of Immunological Methods, 2006, 314, 103-113.	1.4	17
119	CTLA-4 Engagement and Regulatory CD4+CD25+T Cells Independently Control CD8+-Mediated Responses under Costimulation Blockade. Journal of Immunology, 2006, 176, 5240-5246.	0.8	15
120	Tolerizing Effects of Co-stimulation Blockade Rest on Functional Dominance of CD4+CD25+ Regulatory T Cells. Transplantation, 2005, 79, 147-156.	1.0	22
121	Cyclosporine Preserves the Anergic State of Human T Cells Induced by Costimulation Blockade In Vitro. Transplantation, 2005, 80, 522-529.	1.0	10
122	Exon 2 sequence analysis of a novel HLA-DRB1 allele, DRB1*1450. Tissue Antigens, 2005, 66, 332-333.	1.0	4
123	Activation of NK Cells by an Endocytosed Receptor for Soluble HLA-G. PLoS Biology, 2005, 4, e9.	5.6	280
124	CD27/CFSE-Based Ex Vivo Selection of Highly Suppressive Alloantigen-Specific Human Regulatory T Cells. Journal of Immunology, 2005, 174, 7573-7583.	0.8	91
125	Membrane-bound HLA-G activates proliferation and interferon-Â production by uterine natural killer cells. Molecular Human Reproduction, 2004, 10, 189-195.	2.8	100
126	Hormonal stimulation for IVF treatment positively affects the CD56bright/CD56dim NK cell ratio of the endometrium during the window of implantation. Molecular Human Reproduction, 2004, 10, 513-520.	2.8	46

#	Article	IF	CITATIONS
127	Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors. Bone Marrow Transplantation, 2004, 33, 1115-1121.	2.4	10
128	Shift in Expression of HLA-G mRNA Spliceforms in Pregnancies Complicated by Preeclampsia. Journal of the Society for Gynecologic Investigation, 2004, 11, 220-226.	1.7	19
129	A Novel Bispecific Antihuman CD40/CD86 Fusion Protein with T-cell Tolerizing Potential. Transplantation, 2004, 78, 1429-1438.	1.0	6
130	Levels of soluble HLA-G in amniotic fluid are related to the sex of the offspring. International Journal of Immunogenetics, 2003, 30, 163-164.	1.2	7
131	The proportion of follicular fluid CD16+CD56DIM NK cells is increased in IVF patients with idiopathic infertility. Journal of Reproductive Immunology, 2003, 60, 71-84.	1.9	19
132	Analysis of 127 Stem Cell Donations of the Regional Bone Marrow Donor Bank Europdonor Nijmegen, The Netherlands. Leukemia and Lymphoma, 2003, 44, 983-987.	1.3	5
133	IL-15 and Cognate Antigen Successfully Expand De Novo-Induced Human Antigen-Specific Regulatory CD4+ T Cells That Require Antigen-Specific Activation for Suppression. Journal of Immunology, 2003, 171, 6431-6441.	0.8	72
134	Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. Transplantation, 2003, 75, 1581-1590.	1.0	49
135	Detection of HLA-G by a specific sandwich ELISA using monoclonal antibodies G233 and 56B. Molecular Human Reproduction, 2002, 8, 776-784.	2.8	51
136	Altered phenotype of HLA-G expressing trophoblast and decidual natural killer cells in pathological pregnancies. Human Reproduction, 2002, 17, 1072-1080.	0.9	67
137	HLA-DRB1*12 is associated with protection against complicated typhoid fever, independent of tumour necrosis factor α. International Journal of Immunogenetics, 2002, 29, 297-300.	1.2	17
138	Immunoprecipitation and isoelectric focusing of sheep MHC class I antigens reveal higher complexity than serology. International Journal of Immunogenetics, 2002, 29, 391-399.	1.2	5
139	Amniotic fluid soluble human leukocyte antigen G is markedly decreased in offspring with neural tube defects. Early Human Development, 2002, 66, 101-105.	1.8	11
140	HLA-C MISMATCHES INDUCE STRONG CYTOTOXIC T-CELL REACTIVITY IN THE PRESENCE OF AN ADDITIONAL DRB/DQB MISMATCH AND AFFECT NK CELL???MEDIATED ALLOREACTIVITY. Transplantation, 2001, 72, 923-929.	1.0	23
141	A unique second donor splice site in the intron 5 sequence of the HLA-A*11 alleles results in a class I transcript encoding a molecule with an elongated cytoplasmic domain. Tissue Antigens, 2000, 55, 422-428.	1.0	8
142	Peripheral natural killer cytotoxicity and CD56posCD16pos cells increase during early pregnancy in women with a history of recurrent spontaneous abortion. Human Reproduction, 2000, 15, 1163-1169.	0.9	135
143	Cytotoxic T-lymphocyte precursor frequency (CTLp-f) as a tool for distinguishing permissible from non-permissible class I mismatches in T-cell-depleted allogeneic bone marrow transplantation. British Journal of Haematology, 2000, 111, 685-694.	2.5	24
144	Natural killer cell reactivity and HLA-G in recurrent spontaneous abortion. Transplantation Proceedings, 1999, 31, 1838-1840.	0.6	18

#	Article	IF	CITATIONS
145	DPB1*7601, a novel DPB1 variant in the Caucasoid population. Tissue Antigens, 1998, 51, 663-665.	1.0	9
146	Helper and cytotoxic T cell precursor frequencies are not predictive for development of acute graft-versus-host disease after partially T cell-depleted HLA-identical sibling BMT. Bone Marrow Transplantation, 1998, 22, 1049-1055.	2.4	18
147	Fine tuning of antigen-presenting cell-directed monoclonal antibody strategies in the induction of human allospecific T-cell tolerance in vitro. Transplantation Proceedings, 1998, 30, 2447-2449.	0.6	3
148	Definition of an extended MHC class II-peptide binding motif for the autoimmune disease-associated Lewis rat RT1.BL molecule. International Immunology, 1997, 9, 281-290.	4.0	31
149	Selection of Self-reactive Peptides Within Human Aggrecan by use of a HLA-DRB1*0401 Peptide Binding Motif. Journal of Autoimmunity, 1997, 10, 569-578.	6.5	14
150	A single [3H]thymidine-based limiting dilution analysis to determine HTLp and CTLp frequencies for bone marrow donor selection. Bone Marrow Transplantation, 1997, 20, 149-155.	2.4	18
151	Vaccination against feline immunodeficiency virus using fixed infected cells. Veterinary Immunology and Immunopathology, 1995, 46, 139-149.	1.2	16
152	Direct binding of autoimmune disease related T cell epitopes to purified Lewis rat MHC class II molecules. International Immunology, 1994, 6, 751-759.	4.0	62
153	Inhibition of entire myelin basic protein-induced experimental autoimmune encephalomyelitis in Lewis rats by major histocompatibility complex class II-binding competitor peptides. European Journal of Immunology, 1994, 24, 1053-1060.	2.9	9
154	Serological definition of bovine MHC class II polymorphism in Holsteinâ€Friesians. Tissue Antigens, 1994, 43, 229-237.	1.0	5
155	Biochemical characterization of bovine MHC DQ allelic variants by oneâ€dimensional isoelectric focusing. Tissue Antigens, 1994, 44, 100-109.	1.0	19
156	Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone Journal of Experimental Medicine, 1992, 176, 667-677.	8.5	117
157	Retained placenta: an immunological approach. Animal Reproduction Science, 1992, 28, 451-461.	1.5	29
158	Factors affecting occurrence of retained placenta in cattle. Effect of sire on incidence. Animal Reproduction Science, 1991, 25, 11-22.	1.5	19
159	Bovine MHC class II restriction fragment length polymorphism linked to expressed polymorphism. Immunogenetics, 1990, 31, 123-126.	2.4	19
160	Biochemically defined polymorphism of bovine MHC class II antigens. Immunogenetics, 1989, 29, 213-216.	2.4	48
161	Prostaglandin catabolism in the bovine placenta. Placenta, 1988, 9, 297-302.	1.5	9
162	Economic and reproductive consequences of retained placenta in dairy cattle. Veterinary Record, 1988, 123, 53-57.	0.3	41

#	Article	IF	CITATIONS
163	Factors related to the etiology of retained placenta in dairy cattle. Animal Reproduction Science, 1987, 14, 251-262.	1.5	29